카르베딜롤을 함유하는 경구제어 방출형 제제의 제조 및 용출특성

국문 초록 (Abstract)

고혈압 치료제인 카르베딜롤을 모델약물로 하여 새로운 서방성 방출 제어형 매트릭스 정제를 제조하기 위하 여 소수성 서방성 부형제인 Compritol 888 ATO와 친수성 고분자인 hydroxypropyl methyl cellulose (HPMC) 또는 polyethylene oxide (PEO)를 이용하여 방출 제어형 매트릭스 정제를 제조하였다. 카르베딜롤 방출 제어형 매트릭스 정 제의 제조 시 Compritol 888 ATO의 비율과 친수성 고분자의 종류 및 비율, hot melt coating coagglutination (HMCC) rocess의 적용 유무에 따른 카르베딜롤의 방출 양상을 위하여 용출시험기를 사용하여 pH 1.2의 인공위액과 pH 6.8의 인공장액에서 24시간 동안 37℃, 50 rpm으로 용출시험을 실시하였다. 그 결과, HMCC process를 적용한 모든 제제가 약물의 방출 제어에 매우 효과적인 것을 확인하였다. 또한 소수성 서방성 부형제인 Compritol 888 ATO의 비율에 따 라 약물의 방출 양상 및 시간이 기존 일반정제에 비하여 약 95%의 용출률을 나타내었으며 24시간까지 지연됨을 확 인할 수 있었다.

다국어 초록 (Multilingual Abstract)

We prepared sustained release matrix system which contains carvedilol with Compritol 888 ATO used as lipophilic sustained release excipient and hydroxypropyl methyl cellulose (HPMC) or polyethylene oxide (PEO) used as hydrophilic sustained release polymer. Wet granulation compressed method was used for preparing carvedilol sustained release matrix tablets. When carvedilol sustained release matrix tablets were prepared, we evaluated the drug release kinetics which is affected by Compritol 888 ATO ratio, a kind of hydrophilic polymer (HPMC, PEO) and hot melt coating coagglutination (HMCC) process was done. The drug release kinetics was measured for 24 hours in pH 1.2 simulated gastric fluid and pH 6.8 simulated intestinal fluid, using a dissolution tester at 37.5℃ in 50 rpm. Dissolution rate of controlled release matrix tablets of carvedilol was evaluated by paddle method. We confirmed that HMCC process was very effective to controlled release of drugs. The rate of Compritol 888 ATO, as a lipidic material, can control the drug release pattern about the elution rate of 95% and 24 hours delay than that of the normal tablet.

참고문헌 (Reference)

1 손은수, "약물방출제어시스템 개발동향" R&D 2-3, 2004

2 김세미, "딜라트렌 정 12.5밀리그람(카르베딜롤 12.5밀리그람)에 대한 카딜란 정 12.5밀리그람의 생물학적동등성" 한국약제학회 38 (38): 413-419, 2008

3 Jay N. Cohn, "The U.S. Carvedilol Heart Failure Study Group, Safety and efficacy of carvedilol in severe heart failure," 3 : 1997

4 Y. J. Choi, "Randomized, Double-Blind Clinical Trial to Determine the Efficacy of Carvedilol vs. Atenolol in Patients with Stage 1 to 2 Essential Hypertension," 28 (28): 1998

5 G. Neugebauer, "Pharmacokinetics and disposition of carvedilol in human," 10 : 85-88, 1987

6 G. Neugebauer, "Pharmacokinetics and bioavailability of carvedilol in patient with liver cirrhosi" 36 : 148-154, 1988

7 inda S. Henderson, "Pharmacokinetic and Pharmacodynamic Comparison of Controlled-Release Carvedilol and Immediate-Release Carvedilol at Steady State in Patients with Hypertension," 98 (98): 17-26, 2006

8 Mario Grassi, "Modeling of drug release from partially coated matrices made of a high viscosity HPMC" 276 (276): 107-114, 2004

9 J. Siepmann, "Modeling of drug release from delivery systems based on hydroxypropyl methyl cellulose (HPMC)," 48 (48): 139-157, 2001

10 Tetsuya Ozeki, "Mechanism of medicine release from solid dispersion composed of poly(ethylene oxide)-carboxyvinylpolymer interpolymer complex and pH effect on medicine release" 171 (171): 123-132, 1998

11 You Han Bae, "Hydrogel delivery systems based on polymer blends, block co-polymers or interpenetrating networks," 11 (11): 109-135, 1993

12 J. J. Mcphillips, "Effects of carvedilol on blood pressure in patients with mild to moderate hypertension" 36 : 82-91, 1988

13 James E. Udelson, "Compliance with Once Daily Controlled Release vs Twice Daily Immediate Release Carvedilol in Patients with Heart Failure: The CASPER Trial" The CASPER Trial,Journal of Cardiac Failure,Vol.13,No.6,pp.S135 13 (13): 2007

14 James E. Udelson, "Adherence With Once Daily Versus Twice Daily Carvedilol in Patients With Heart Failure: The Compliance and Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients With Heart Failure (CASPER) Trial" 15 (15): 385-393, 2009